130693-82-2 Usage
Description
Dorzolomide hydrochloride, also known as Dorzolamide HCl, is a potent carbonic anhydrase inhibitor that was introduced in the U.S.A. as eye drops for the treatment of open-angle glaucoma and ocular hypertension. It is available as a white powder and is used in ophthalmic solutions to lower increased intraocular pressure. Dorzolamide hydrochloride is effective as a single therapy or in combination with β-blockers.
Uses
Used in Ophthalmology:
Dorzolomide hydrochloride is used as an antiglaucoma agent for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. It acts as a carbonic anhydrase inhibitor, which helps in lowering intraocular pressure (IOP) and has been shown to be effective throughout the day.
Used in Sports Doping:
Dorzolomide hydrochloride is used as a diuretic in sports doping to reduce weight or anabolic androgenic steroid-induced water retention, or as a masking agent. It is categorized as a carbonic anhydrase inhibitor diuretic and is intended for use in analytical forensic applications.
Used in Research and Development:
Dorzolomide hydrochloride is also used as an analytical reference standard and a general research tool for the development of new pharmaceuticals and the study of its properties and applications in various fields.
Used in Pain Management:
Dorzolomide hydrochloride is used as an analgesic, providing relief from pain in various conditions.
Originator
Merck (U.S.A.)
Manufacturing Process
Manufacturing process for Dorzolamide hydrochloride includes these steps as follows: Step A: Sulfuric Acid Ritter Procedure;Step B: Sulfonylation Procedure Step C: Chlorosulfonylation Procedure;Step D: Amidation Procedure;Step E: Reduction via Borane Generated in situ Procedure;Step F: Maleate Salt Formation Procedure;Step G: Crude Hydrochloride Salt Formation;Step H: Recrystallization Procedure.
Therapeutic Function
Antiglaucoma
Veterinary Drugs and Treatments
Dorzolamide is often used in the contralateral eye of a dog with
primary glaucoma to prevent development of bilateral disease. It
is also an excellent agent to consider for most secondary glaucomas
in dogs and cats because it has no effect on pupil size. Like the
related oral carbonic anhydrase inhibitors (dichlorphenamide or
Daranide?, methazolamide or Neptazane?), dorzolamide decreases
aqueous humor production by the ciliary body epithelium by altering
pH and affecting the H+/Na+ active transport exchange mechanism.
Oral carbonic anhydrase inhibitors cause numerous systemic
side effects such as metabolic acidosis and panting, diarrhea, vomiting,
anorexia and others, all of which can be avoided with topical
carbonic anhydrase inhibitors.
Check Digit Verification of cas no
The CAS Registry Mumber 130693-82-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,6,9 and 3 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 130693-82:
(8*1)+(7*3)+(6*0)+(5*6)+(4*9)+(3*3)+(2*8)+(1*2)=122
122 % 10 = 2
So 130693-82-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H16N2O4S3.ClH/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16;/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16);1H/t6-,8-;/m0./s1
130693-82-2Relevant articles and documents
Chiral synthesis method of dorzolamide hydrochloride
-
Paragraph 0023-0027, (2021/09/04)
The invention relates to a chiral synthesis method of dorzolamide hydrochloride, which comprises the following steps: (1) by taking a compound I that is (6S)-4-carbonyl-5,6-dihydro-4H-6-methyl-thieno[2,3b] thiopyran-2-sulfonamide-7,7-dioxide as an initial raw material, carrying out imidization reaction on the initial raw material and ethylamine to obtain a compound II that is (6S)-4-ethyl imino-5,6-dihydro-4H-6-methyl-thieno[2, 3b]thiopyran-2-sulfonamide-7,7-dioxide; (2) carrying out asymmetric hydrogenation reaction on the compound II obtained in the step (1), a catalyst and a chiral ligand (R)-(+)-1,1'-binaphthyl-2'-isopropoxy-2-diphenylphosphine to obtain a compound III that is dorzolamide; and (3) mixing the compound III obtained in the step (2) with hydrochloric acid, acidifying, washing and drying to obtain a compound IV, namely dorzolamide hydrochloride. The synthesis method is simple and easy to implement, high in chiral selectivity and low in cost, and the obtained dorzolamide hydrochloride is high in purity and suitable for industrial production.
PROCESS FOR THE PREPARATION OF DORAOLZMIDE HYDROCHLORIDE
-
Page/Page column 13, (2018/04/21)
The present invention discloses an improved process for the preparation of dorzolamide hydrochloride the compound of Formula I.
PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED OXAMIDES
-
Page/Page column 15; 16, (2014/01/18)
The present invention relates to a chiral oxamide of formula (I) useful as an intermediate in the preparation of dorzolamide, and to the preparation thereof. The invention also relates to the preparation of dorzolamide, to the hydrochloride salt thereof, and to the active ingredient contained in a drug useful in the treatment of glaucoma, by means of the intermediate of formula (I).